Artivion reported double-digit year-over-year revenue growth in Q4 2025 driven by strong uptake of its vascular graft portfolio. Management highlighted raw-material cost inflation and logistical constraints that squeezed gross margins and outlined a process-automation initiative to lower operating expenses and protect profitability.